Adaptimmune Therapeutics PLC (ADAP)
1.075
+0.02
(+1.42%)
USD |
NASDAQ |
Apr 26, 16:00
1.08
0.00 (0.00%)
After-Hours: 20:00
Adaptimmune Therapeutics Profit Margin (Quarterly): -20.74K% for Dec. 31, 2023
Profit Margin (Quarterly) Chart
Historical Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -20.74K% |
| September 30, 2023 | -623.0% |
| June 30, 2023 | -416.9% |
| March 31, 2023 | 2.18% |
| December 31, 2022 | -265.2% |
| September 30, 2022 | -591.1% |
| June 30, 2022 | -803.9% |
| March 31, 2022 | -1.41K% |
| December 31, 2021 | -2.74K% |
| September 30, 2021 | -3.52K% |
| June 30, 2021 | -1.26K% |
| March 31, 2021 | -8.70K% |
| December 31, 2020 | -2.44K% |
| September 30, 2020 | -2.97K% |
| June 30, 2020 | -5.95K% |
| March 31, 2020 | -3.70K% |
| December 31, 2019 | -4.03K% |
| September 30, 2019 | -16.58K% |
| Date | Value |
|---|---|
| June 30, 2019 | -26.17K% |
| March 31, 2019 | |
| December 31, 2018 | -2.45K% |
| September 30, 2018 | 12.85% |
| June 30, 2018 | -485.1% |
| March 31, 2018 | -257.2% |
| December 31, 2017 | -638.5% |
| September 30, 2017 | -3.23% |
| June 30, 2017 | -574.1% |
| March 31, 2017 | -762.4% |
| December 31, 2016 | -180.6% |
| September 30, 2016 | -765.5% |
| June 30, 2016 | -6.74K% |
| March 31, 2016 | -533.8% |
| September 30, 2015 | -34.50% |
| December 31, 2014 | -70.19% |
| September 30, 2014 | -213.0% |
Profit Margin Definition
Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.
Profit Margin (Quarterly) Range, Past 5 Years
-26.17K%
Minimum
Jun 2019
2.18%
Maximum
Mar 2023
-5.42K%
Average
-2.74K%
Median
Dec 2021
Profit Margin (Quarterly) Benchmarks
Profit Margin (Quarterly) Related Metrics
| Return on Equity | -135.5% |
| Return on Assets | -36.99% |
| Return on Invested Capital | -135.5% |
| Operating Margin (Quarterly) | -21.58K% |
| Return on Net Operating Assets | -90.76% |